KMX
58
4
EQIX
58
-11
AZO
62
-3
MRK
46
14
CMCSA
53
-10
GPC
51
-6
NVDA
52
-2
BRK.B
52
2
EFX
66
-14
DFS
53
-24
AME
51
-3
INTC
45
-2
TSCO
46
-4
HRB
52
-2
ADM
34
-2
DE
50
-18
CL
50
-25
EMN
46
-27
MDLZ
51
-2
HAS
46
-2
KMX
58
4
EQIX
58
-11
AZO
62
-3
MRK
46
14
CMCSA
53
-10
GPC
51
-6
NVDA
52
-2
BRK.B
52
2
EFX
66
-14
DFS
53
-24
AME
51
-3
INTC
45
-2
TSCO
46
-4
HRB
52
-2
ADM
34
-2
DE
50
-18
CL
50
-25
EMN
46
-27
MDLZ
51
-2
HAS
46
-2
Financhill
Back

FinVolution Group 10K Form

Buy
89

FINV
FinVolution Group

Last Price:
$10.04
Seasonality Move:
5.65%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive FINV News And Ratings

See the #1 stock for the next 7 days that we like better than FINV

FINV Financial Statistics

Sales & Book Value

Annual Sales: $1.8B
Cash Flow: $20.8M
Price / Cash Flow: 6.54
Annual Sales: $8.02
Price / Book: 1.25

Profitability

EPS (TTM): 1.25410
Net Income (TTM): $332.1M
Gross Margin: $1.5B
Return on Equity: 16.39%
Return on Assets: 10.7%

FinVolution Group Earnings Forecast

Key FinVolution Group Financial Ratios

  • The Gross Profit Margin over the past 10 years for FINV is 81.77%.
  • The Selling, General & Administrative Expenses for FINV have been equal to 18.58% of Gross Profit Margin.
  • The Research & Development expenses have been 3.80% of Revenue.
  • The Net Earning history of FINV is 18.24% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 5 years.

FinVolution Group Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Consumer Finance
Sector: Financials
Current Symbol: FINV
CUSIP: 31810T
Website: finvgroup.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.89
Quick Ratio: 3.44

Price-to-Earnings

Trailing P/E Ratio: 7.92
Forward P/E Ratio: 5.59

FINV Technical Analysis vs Fundamental Analysis

Buy
89
FinVolution Group (FINV) is a Buy

Is FinVolution Group a Buy or a Sell?

  • FinVolution Group stock is rated a Buy
    The current FinVolution Group [FINV] share price is $9.99. The Score for FINV is 89, which is 78% above its historic median score of 50, and infers lower risk than normal.